Aurinia Pharmaceuticals, Inc. (AUPH)
16.86
-0.47
(-2.71%)
USD |
NASDAQ |
Oct 23, 16:00
16.86
0.00 (0.00%)
After-Hours: 20:00
Aurinia Pharmaceuticals Enterprise Value : 1.862B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 1.862B |
| October 22, 2026 | 1.924B |
| October 21, 2026 | 1.867B |
| October 20, 2026 | 1.846B |
| October 19, 2026 | 1.813B |
| October 16, 2026 | 1.815B |
| October 15, 2026 | 1.845B |
| October 14, 2026 | 1.829B |
| October 13, 2026 | 1.795B |
| October 12, 2026 | 1.821B |
| October 09, 2026 | 1.834B |
| October 08, 2026 | 1.777B |
| October 07, 2026 | 1.749B |
| October 06, 2026 | 1.706B |
| October 05, 2026 | 1.710B |
| October 02, 2026 | 1.725B |
| October 01, 2026 | 1.741B |
| September 30, 2026 | 1.773B |
| September 29, 2026 | 1.803B |
| September 28, 2026 | 1.817B |
| September 25, 2026 | 1.806B |
| September 24, 2026 | 1.827B |
| September 23, 2026 | 1.801B |
| September 22, 2026 | 1.837B |
| September 21, 2026 | 1.829B |
| Date | Value |
|---|---|
| September 18, 2026 | 1.867B |
| September 17, 2026 | 1.875B |
| September 16, 2026 | 1.875B |
| September 15, 2026 | 1.765B |
| September 14, 2026 | 1.802B |
| September 11, 2026 | 1.761B |
| September 10, 2026 | 1.762B |
| September 09, 2026 | 1.781B |
| September 08, 2026 | 1.757B |
| September 04, 2026 | 1.758B |
| September 03, 2026 | 1.763B |
| September 02, 2026 | 1.786B |
| September 01, 2026 | 1.754B |
| August 31, 2026 | 1.762B |
| August 28, 2026 | 1.786B |
| August 27, 2026 | 1.811B |
| August 26, 2026 | 1.819B |
| August 25, 2026 | 1.847B |
| August 24, 2026 | 1.823B |
| August 21, 2026 | 1.834B |
| August 20, 2026 | 1.916B |
| August 19, 2026 | 1.770B |
| August 18, 2026 | 1.654B |
| August 17, 2026 | 1.653B |
| August 14, 2026 | 1.677B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| enGene Therapeutics, Inc. | -128.59M |
| Medicus Pharma Ltd. | 155.00M |
| Xenon Pharmaceuticals, Inc. | 2.495B |
| Psyence Biomedical Ltd. | -- |
| Agenus, Inc. | 534.42M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 37.41M |
| Revenue (Quarterly) | 83.22M |
| Total Expenses (Quarterly) | 45.81M |
| EPS Diluted (Quarterly) | 0.2802 |
| Gross Profit Margin (Quarterly) | 92.12% |
| Profit Margin (Quarterly) | 44.96% |
| Earnings Yield | 13.57% |
| Operating Earnings Yield | 6.12% |
| Normalized Earnings Yield | 13.57 |